Abatacept for the treatment of systemic lupus erythematosus

References

• Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308–318.
   PubMed Web of Science ®Google Scholar
• Yurkovich M, Vostretsova K, Chen W, et al. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2014;66(4):608–616.
   PubMed Web of Science ®Google Scholar
• Mak A, Isenberg DA, Lau C-S. Global trends, potential mechanisms and early detection of organ damage in SLE. Nat Rev Rheumatol. 2013;9(5):301–310.
   PubMed Web of Science ®Google Scholar
• Aringer M, Burkhardt H, Burmester GR, et al. Current state of evidence on ‘off-label’ therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland – a consensus report. Lupus. 2012 Apr;21(4):386–401.
   PubMed Web of Science ®Google Scholar
• Papagoras C, Drosos AA. Abatacept: a biologic immune modulator for rheumatoid arthritis. Expert Opin Biol Ther. 2011;11(8):1113–1129.
   PubMed Web of Science ®Google Scholar
• Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56(7):481–490.
   PubMed Web of Science ®Google Scholar
• Herrero-Beaumont G, Martínez Calatrava MJ, Castañeda S. Abatacept mechanism of action: concordance with its clinical profile. Reumatol Clin. 2012;8(2):78–83.
   PubMedGoogle Scholar
• Hoi A, Littlejohn G. Is there still a role for abatacept in the treatment of lupus? Expert Opin Biol Ther. 2014;14(9):1345–1350.
   PubMed Web of Science ®Google Scholar
• Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis. 2008 Feb;67(2):195–205.
   PubMed Web of Science ®Google Scholar
• Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(4):620–625.
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121–2131.
   PubMed Web of Science ®Google Scholar
• Gourley MF, Austin HA 3rd, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125(7):549–557.
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Austin HA 3rd, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340(8822):741–745.
   PubMed Web of Science ®Google Scholar
• Sthoeger Z, Sharabi A, Mozes E. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus. J Autoimmun. 2014;54:60–71.
   PubMed Web of Science ®Google Scholar
• Manzi S, Sánchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833–1838.
   PubMed Web of Science ®Google Scholar
• Keating GM. Abatacept: a review of its use in the management of rheumatoid arthritis. Drugs. 2013;73(10):1095–1119.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker J-C, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114–1123.
   PubMed Web of Science ®Google Scholar
• Daikh DI, Finck BK, Linsley PS, et al. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol. 1997;159(7):3104–3108.
   PubMed Web of Science ®Google Scholar
• Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol. 2001;166(5):2913–2916.
   PubMed Web of Science ®Google Scholar
• Hoi AY, Littlejohn GO. Abatacept in the treatment of lupus. Expert Opin Biol Ther. 2012;12(10):1399–1406.
   PubMed Web of Science ®Google Scholar
• Agency EM Orencia Scientific Discussion. 2007; [ cited 2015 Aug 30]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000701/WC500048938.pdf
   Google Scholar
• Company B-MS. Orencia (Abatacept). 2007 [ cited 2015 Aug 30]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125118s0016lbl.pdf
   Google Scholar
• Razmara M, Hilliard B, Ziarani AK, et al. CTLA-4 x Ig converts naive CD4+CD25- T cells into CD4+CD25+ regulatory T cells. Int Immunol. 2008;20(4):471–483.
   PubMed Web of Science ®Google Scholar
• Reiser J, Von Gersdorff G, Loos M, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest. 2004;113(10):1390–1397.
   PubMed Web of Science ®Google Scholar
• Yu -C-C, Fornoni A, Weins A, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2013;369(25):2416–2423.
   PubMed Web of Science ®Google Scholar
• Furie R, Nicholls K, Cheng -T-T, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014;66(2):379–389.
   PubMed Web of Science ®Google Scholar
• Vicente Rabaneda EF, Herrero-Beaumont G, Castañeda S. Update on the use of abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2013;9(7):599–621.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(10):3077–3087.
   PubMed Web of Science ®Google Scholar
• ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol. 2014;66(11):3096–3104.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215–1226.
   PubMed Web of Science ®Google Scholar
• Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103–1112.
   PubMed Web of Science ®Google Scholar
• Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012;64(11):3660–3665.
   PubMed Web of Science ®Google Scholar
• Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum. 2006;54(2):421–432.
   PubMed Web of Science ®Google Scholar
• Hochberg M, Westhovens R, Aranda R, et al. Long-term safety of abatacept: integrated analysis of clinical program data of up to 7 years of treatment. Arthritis Rheum. 2010;62(Suppl 10):S164.
   Google Scholar
• Smitten A, Westhovens R, Hochberg M, et al. Serious infections and malignancies during long-term exposure to abatacept. Ann Rheum Dis. 2010;69(Suppl 3):541.
   Google Scholar
• Garin EH, Reiser J, Cara-Fuentes G, et al. Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatr Nephrol. 2015;30(3):469–477.
   PubMed Web of Science ®Google Scholar
• Masson P, Henderson L, Chapman JR, et al. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev. 2014;11:CD010699.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers S. Efficacy and safety study of abatacept to treat lupus nephritis. 2017. [cited 2016 Jan 21]. Available at http://ClinicalTrials.gov/show/NCT01714817
   Google Scholar
• Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, et al. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2014;53(8):1470–1476.
   PubMed Web of Science ®Google Scholar